FARETINA-DME- Six-Month Treatment Patterns and Outcomes in Patients with Diabetic Macular Edema Treated with Faricimab: an IRIS RegistryTM Analysis

Theme: Retina*
What: Retina
Part of: Retina II: Stamping out Blindness and Restoring Sight / Rétine II: Lutter contre la cécité et redonner la vue
When: 6/1/2024, 04:15 PM - 05:45 PM
Where: Room | Salle 713 AB

Abstract

Purpose

Anti-Vascular Endothelial Growth Factor (VEGF) intravitreal agents for diabetic macular edema (DME) require frequent injections to mitigate vision loss. Faricimab is the only bispecific antibody for intraocular use that independently binds and neutralizes both angiopoietin-2 and VEGF-A. Real-world data on treatment patterns and outcomes of faricimab continues to grow. This analysis describes the largest real-world evaluation of injection frequency and clinical response of DME patients initiating faricimab.

 

Methods

FARETINA-DME is a retrospective real world study using data from the IRIS registry. Data analyzed February-September 2022 identified faricimab starts among patients diagnosed with DME. Rules-based text search using regular expression keywords was used to identify faricimab use. Patients with ≥ 12 months of electronic health record data prior to initiation and known laterality were included.  Patients with ≥ 6 months of follow-up data were included in injection intervals and best documented visual acuity (BDVA) analyses. Injection intervals were categorized as “extended” if any interval was >6 weeks apart.

 

Results

3,229 eyes (2,543 patients) were treated with faricimab for DME, with a mean (SD) of 2.9 (1.7) faricimab injections over a mean (SD) of 123.9 (65.5) days of follow-up. 515 (19.1%) of eyes were anti-VEGF treatment naïve; 2,176 (80.9%) were previously treated. Nearly half of eyes (48.2% treatment naïve; 44.3% previously treated) had 20/40 or better BDVA at faricimab initiation. Mean (SD) injection frequency of anti-VEGFs in the prior 12 months was 5.4 (2.9) injections with a mean (SD) interval length of 52.9 (38.9) days. Most (64.3%) previously treated eyes were treated with aflibercept.

 

128 (17.5%) treatment naïve and 605 (82.5%) previously treated eyes had ≥ 6 months of follow-up, with a mean (SD) 4.2 (2.2) injections. Mean (SD) change in BDVA after 4 injections was 0.8 (10.6) letter for previously treated eyes and 0.1 (9.5) letters in treatment naïve eyes. 92 (71.9%) of treatment naïve eyes (436 (72.1%) of previously treated eyes) “extended” their injection interval within their first 2 injections.

 

Conclusions

Over 3,000 eyes were treated with faricimab for DME in the US through September 2022. Among eyes with ≥ 6 months of follow-up, vision stability was observed while a majority of eyes began extending treatment intervals during four initial doses. Early treatment extensions may indicate a positive anatomical response to faricimab in DME patients.

Presenter(s)

Presenting Author: Keyvan Koushan

Additional Author(s):

Clare Bailey, University Hospitals Bristol NHS Foundation Trust, Bristol, UK

David Tabano, Genentech, Inc., South San Francisco, CA, USA

Durga Borkar, Duke University Eye Center, Holly Springs, NC, USA

Vincent Garmo, Genentech, Inc., South San Francisco, CA, USA

Ayesha Ahmed, Genentech, Inc., South San Francisco, CA, USA

Rachel Myers, Verana Health, San Francisco, CA, USA

Andrew LaPrise, Verana Health, San Francisco, CA, USA

Ferhina Ali, Department of Ophthalmology, New York Medical College, Valhalla, NY

Theodore Leng, Verana Health, San Francisco, CA, USA; Byers Eye Institute, Stanford University School of Medicine, Palo Alto, CA, USA.

Rishi P Sing, Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic, Cleveland, OH, USA

---